SOCS3 and neoplasm: The FXR agonist obeticholic acid (OCA) induces cell cycle arrest and suppresses tumor cell invasion via STAT3 dephosphorylation and SOCS3 upregulation, concomitant with reduced IL-6/STAT3 signaling and pro-inflammatory cytokine (IL-1β, IL-6) secretion [132].